Alebund's AP301 NDA Accepted for Review by China's NMPA

NDA FilingAP301Positive

AI Analysis

Summary

Alebund Pharmaceuticals announced that its AP301 capsules NDA has been accepted for review by China's NMPA. AP301 is a novel oral iron-based phosphate binder for renal disease management.

Outcome Details

NDA accepted for review by China's NMPA

Importance:6/10

Sentiment:

0.60

ChinaNMPAregulatoryNDArenal diseasephosphate binder

Related Companies

$JHPCY $CHHE

Read the original article

Published by PR Newswire Clinical Trials on August 7, 2026 10:34 AM

Read Original